# US 12,497,361 B2 · Crystalline tryptamine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,497,361 B2
- Document ID: US12497361B2
- Status: Granted
- Kind: B2
- Application number: 18/700,875
- Filed: 2022-10-13
- Published: 2024-12-12
- Granted: 2025-12-16
- Earliest claimed: 2021-10-15
- Assignees: Caamtech, Inc.
- Applicants: Caamtech, Inc.
- Inventors: Andrew R. Chadeayne
- Web page: https://patentgrep.com/patent/US12497361B2

## CPC

- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 209/16: Tryptamines
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- C07C 57/15: Fumaric acid
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The disclosure relates to 2-(5-hydroxy-1H-indol-3-yl)ethan-1-aminium hydrate chloride (5-HT hydrochloride hydrate) and its crystalline form 1, and to pharmaceutical compositions containing 5-HT hydrochloride hydrate or its crystalline form 1 and to methods of treatment using them. The disclosure further relates to crystalline form 1 of (2E)-but-2-enedioic acid bis({2-[4-(acetyloxy)-1H-indol-3-yl]ethyl}(ethyl)propylazanium) (2E)-but-2-enedioate (4-AcO-EPT fumarate fumaric acid), and to pharmaceutical compositions containing crystalline form 1 of 4-AcO-EPT fumarate fumaric acid and to methods of treatment using it. The disclosure further relates to [2-(1H-indol-3-yl)ethyl](methyl)propylazanium iodide (MPT iodide) and its crystalline form 1, and to pharmaceutical compositions containing MPT iodide or its crystalline form 1 and to methods of treatment using them. The disclosure further relates to bis(ethyl[2-(1H-indol-3-yl)ethyl]propylazanium) (2E)-but-2-enedioate (EPT fumarate) and its crystalline form 1, and to pharmaceutical compositions containing EPT fumarate or its crystalline form 1 and to methods of treatment using them. EPT fumarate is a novel compound and crystalline form.

## Claims

### Claim 1

Crystalline form 1 of [2-(1H-indol-3-yl)ethyl](methyl)propylazanium iodide (MPT iodide), characterized by at least one of:
an orthorhombic crystal system at a temperature of about 297 K;
a P212121 space group at a temperature of about 297 K;
unit cell dimensions a=8.1126 (3) Å, b=8.7837 (4) Å, and c=21.1953 (8) Å;
an x-ray powder diffraction (XRPD) pattern substantially similar to FIG. 10; or
an X-ray powder diffraction pattern characterized by peaks at 8.3, 11.7, 13.1, and 14.9°2θ±0.2°2θ.

### Claim 2 (depends on 1)

A composition comprising crystalline form 1 of MPT iodide according to claim 1 and an excipient.

### Claim 3 (depends on 1)

A composition comprising crystalline form 1 of MPT iodide according to claim 1 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, or (i) a purified hericenone.
